Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.49 |
| ▸ | LIPC | P11150 | 2/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859366 | 0.88 | PAK4 (0.46) | PAK4NAMPTPAK1LIPCFASN | |
| SCHEMBL19753621 | 0.87 | PAK4 (0.47) | PAK4NAMPTPAK1LIPCSLC6A7 | |
| SCHEMBL18541435 | 0.87 | PAK4 (0.48) | PAK4NAMPTPAK1LIPCSLC6A7 | |
| SCHEMBL19742287 | 0.86 | PAK4 (0.40) | PAK4NAMPTPAK1LIPCFASN | |
| SCHEMBL19078998 | 0.84 | NAMPT (0.58) | PAK4NAMPTPAK1LIPCHDAC3 | |
| SCHEMBL17844682 | 0.84 | PAK4 (0.47) | PAK4NAMPTPAK1LIPCSLC6A7 | |
| SCHEMBL19079065 | 0.84 | NAMPT (0.46) | PAK4NAMPTPAK1HDAC1 | |
| SCHEMBL19066883 | 0.82 | PAK4 (0.69) | PAK4NAMPTPAK1LIPCSLC6A7 | |
| SCHEMBL17859225 | 0.82 | NAMPT (0.76) | PAK4NAMPTPAK1LIPCHDAC3 | |
| SCHEMBL18541429 | 0.82 | PAK4 (0.54) | PAK4NAMPTPAK1LIPCHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | PAK4 1077/4885NAMPT 1646/4885PAK1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.